Join to View Full Profile
8220 Walnut Hill LnDallas, TX 75231
Phone+1 214-739-4175
Fax+1 214-987-4161
Dr. Strauss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1979
Baylor University Medical CenterResidency, Internal Medicine, 1974 - 1976
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1972 - 1973
New York University School of MedicineClass of 1972
Certifications & Licensure
TX State Medical License 1974 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsNemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20 - 1 citationsPhase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-09-01 - Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-08-01
Press Mentions
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
